When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.

Slides:



Advertisements
Similar presentations
Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Sep. 16, 2005 Lilly Yue, Ph.D.* CDRH, FDA, Rockville MD * No official support.
Advertisements

The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,
patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of.
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
PRE-STRATIFIED RANDOMIZATION IS NOT NECESSARY FOR LARGE CLINICAL TRIALS Brent Leininger, Patrick Kurkiewicz, Lifeng Lin, Xiang Li, Bryan Trottier Jr, Yuanyuan.
Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
M2 Medical Epidemiology
1 Arlene Ash QMC - Third Tuesday September 21, 2010 (as amended, Sept 23) Analyzing Observational Data: Focus on Propensity Scores.
The golden hour(s) for severe sepsis and septic shock treatment
1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Clinical Trial Results. org Based on the Iron (Fe) and Atherosclerosis Study (FeAST) Leo R. Zacharski, MD; Bruce K. Chow, MS; Paula S. Howes, MS, APRN;
ARISTOTLE TTR Subanalysis
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009.
Journal Club Alcohol and Health: Current Evidence May–June 2005.
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2011.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2010.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2009.
Stratified Sampling Lecturer: Chad Jensen. Sampling Methods SRS (simple random sample) SRS (simple random sample) Systematic Systematic Convenience Convenience.
5.10: Stratification after Selection of Sample – Post Stratification n Situations can arise in which we cannot place sampling units into their correct.
Sample Size Determination
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
EVIDENCE BASED MEDICINE
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2012.
Ofner, IMI Determining the Parameter Settings of Different Randomization Methods for Specific Study Designs Petra Ofner-Kopeinig, Maximilian Errath and.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Article Review Cara Carty 09-Mar-06. “Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Adaptive randomization
1 THE ROLE OF COVARIATES IN CLINICAL TRIALS ANALYSES Ralph B. D’Agostino, Sr., PhD Boston University FDA ODAC March 13, 2006.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2015.
4S: Scandinavian Simvastatin Survival Study
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
When Is Stratification Detrimental to a Clinical Trial Design? Part I Gretchen Marcucci, M.S. Biostatistician, Rho, Inc. and Katherine L. Monti, Ph.D.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
Lecture 4 Forestry 3218 Avery and Burkhart, Chapter 3 Shiver and Borders, Chapter 5 Forest Mensuration II Lecture 4 Stratified Random Sampling.
بسم الله الرحمن الرحیم.
Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:
Outline of Stratification Lectures Definitions, examples and rationale (credibility) Implementation –Fixed allocation (permuted blocks) –Adaptive (minimization)
Article Title Resident Name, MD SVCH6/13/2016 Journal Club.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2013.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Risk Stratification in Stage II Colon Cancer Patients Ramzi Amri, MD, PhD; Liliana G Bordeianou, MD, MPH; and David L Berger, MD Massachusetts General.
Patient Focused Drug Development An FDA Perspective
Alcohol, Other Drugs, and Health: Current Evidence
Successful CTO PCI Associated with Lower Mortality Risk
The 4th ICTMC & 38th Annual Meeting of SCT
Elaine M Pascoe, Darsy Darssan, Liza A Vergara
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
Clinical factors associated with long-term mortality following vascular surgery: Outcomes from The Coronary Artery Revascularization Prophylaxis (CARP)
Flow Diagram of the Trial Selection Process
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
Journal Editor Perspectives
Presentation transcript:

When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1

Stratification Why? – Achieve balance between groups on factors associated with the response (prognostic variables) How? – Strata created based on prognostic factors Pre-Stratification – Stratification before treatment allocation; accounted for in analysis Post-Stratification – Treatment allocation without strata; stratification in analysis

When to Pre-Stratify Aims: – Reduction in variability (balance of prognostic factors between treatment groups) – Increase in power Conditions: – Known salient prognostic variables Ex: Multiple study sites – Allows for dropping or adding sites during trial (FDA.gov) Ex: Gender, age groups, etc. – Focus on few prognostic variables – More important in smaller study size Kernan et al 1999

Example: CARP Trial

The Study Study Question – Is coronary re-vascularization appropriate in patients with stable coronary artery disease prior to an elective major vascular surgery? Study Design – Randomized, multi-center phase III trial – Intervention Coronary re-vascularization prior to elective surgery No coronary re-vascularization prior to elective surgery – Primary endpoint = long-term mortality Pre-stratification: – Center (18 VA Medical Centers) – Prognostic factor: Type of elective vascular surgery (intraabdominal or infrainguinal)

On Stratification Center 1 Vascular Intervention Planned Intrabdominal Infrainguinal Pre-Strata 1: Center Pre-Strata 2: Vascular Surgery Randomize Yes No Yes No Intervention: Re-vascularization

Results of Stratification

Why not post-stratify? Higher risk for imbalance in vascular surgery type getting different study intervention – Could skew the primary outcome Center 1 Outcome Intrabdominal Infrainguinal Pre-Strata: Center Post-Strata: Vascular Surgery Randomize Yes No Intervention: Re-vascularization

Problems with Pre-Stratification Requires baseline values for prognostic variables prior to randomization Precise stratum definition can be difficult More administrative work Small gain in power for large trial Can diminish power if too many strata

Summary When Should a Clinical Trial Design with Pre- Stratification be Used? – Multi-center studies – Smaller sample size with known prognostic factors – Known prognostic factors that may be difficult to post-stratify